Home/Filings/4/0001593968-24-000196
4//SEC Filing

Douglas Earl Martin 4

Accession 0001593968-24-000196

CIK 0001737287other

Filed

Jan 30, 7:00 PM ET

Accepted

Jan 31, 5:48 PM ET

Size

6.8 KB

Accession

0001593968-24-000196

Insider Transaction Report

Form 4
Period: 2024-01-25
Douglas Earl Martin
SVP, General Counsel
Transactions
  • Award

    Stock Option (Right to buy)

    2024-01-25+147,778147,778 total
    Exercise: $3.20Exp: 2034-01-25Common Stock (147,778 underlying)
  • Award

    Common Stock

    2024-01-25+41,800477,634 total
Footnotes (1)
  • [F1]1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.

Issuer

Allogene Therapeutics, Inc.

CIK 0001737287

Entity typeother

Related Parties

1
  • filerCIK 0001362155

Filing Metadata

Form type
4
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 5:48 PM ET
Size
6.8 KB